As there are no specific guidelines for the type of clone as well as for the cut-off points for TPS/CPS scoring for PD-L1 expression for thyroid carcinoma, unlike other carcinomas, such as lung, breast, and urothelial carcinoma, we evaluated PD-L1 at various cut-off values of ≥1%, ≥10%, ≥25%, and ≥50%. This evidence concerns the gene CD274 and urothelial carcinoma.